News - Roche

Filter

Current filters:

Roche

Popular Filters

151 to 175 of 382 results

Roche granted EU approval for Perjeta; board appointments

06-03-2013

The European Medicines Agency has approved Swiss drug major Roche's (ROG: SIX) Perjeta (pertuzumab) for…

BiotechnologyEuropeManagementOncologyPerjetaPharmaceuticalRegulationRoche

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Roche aims for expansion in Russia; Pharmsynthez production plans

20-02-2013

Swiss pharmaceutical major Roche (ROG: SIX) plans to accelerate its expansion into the Russian pharmaceutical…

EuropeMabTheraPharmaceuticalPharmsynthezProductionRoche

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

BRIC countries' breast cancer market to see 8% annual growth to 2017

14-02-2013

The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow…

GlaxoSmithKlineGlobalHerceptinMarkets & MarketingOncologyPharmaceuticalRocheTykerb

Genentech enters $111 million drug discovery pact with RQx Pharma

13-02-2013

California, USA-based privately-held RQx Pharmaceuticals said yesterday that it has entered into a drug…

BiotechnologyGenentechLicensingRocheRQx Pharmaceuticals

Cytomegalovirus infections market completely controlled by Roche's Valcyte

05-02-2013

The global cytomegalovirus (CMV) infections market has been forecast to increase at a compound annual…

Anti-viralsletermovirMarkets & MarketingMerck & CoPharmaceuticalRocheValcyte

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Roche sees strong 2012 performance in USA but slowdown in Europe

31-01-2013

Swiss drug major Roche (ROG: SIX) has reported 2012 financial results with 4% growth in group sales to…

BiotechnologyFinancialPharmaceuticalRoche

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

Roche recruits US academic to spice up R&D; changes at AstraZeneca

16-01-2013

In a bid to invigorate its R&D productivity, Swiss drug major Roche (ROG: SIX) has appointed a well-known…

AstraZenecaManagementPharmaceuticalRoche

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

151 to 175 of 382 results

Back to top